List of Tables
Table 1. Global MET Inhibitors for Lung Cancer Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global MET Inhibitors for Lung Cancer Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global MET Inhibitors for Lung Cancer Market Competitive Situation by Manufacturers in 2024
Table 4. Global MET Inhibitors for Lung Cancer Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global MET Inhibitors for Lung Cancer Sales Market Share by Manufacturers (2020-2025)
Table 6. Global MET Inhibitors for Lung Cancer Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global MET Inhibitors for Lung Cancer Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market MET Inhibitors for Lung Cancer Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of MET Inhibitors for Lung Cancer, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of MET Inhibitors for Lung Cancer, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of MET Inhibitors for Lung Cancer, Product Type & Application
Table 12. Global Key Manufacturers of MET Inhibitors for Lung Cancer, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global MET Inhibitors for Lung Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in MET Inhibitors for Lung Cancer as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global MET Inhibitors for Lung Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global MET Inhibitors for Lung Cancer Sales by Region (2020-2025) & (K Units)
Table 18. Global MET Inhibitors for Lung Cancer Sales Market Share by Region (2020-2025)
Table 19. Global MET Inhibitors for Lung Cancer Sales by Region (2026-2031) & (K Units)
Table 20. Global MET Inhibitors for Lung Cancer Sales Market Share by Region (2026-2031)
Table 21. Global MET Inhibitors for Lung Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global MET Inhibitors for Lung Cancer Revenue Market Share by Region (2020-2025)
Table 23. Global MET Inhibitors for Lung Cancer Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global MET Inhibitors for Lung Cancer Revenue Market Share by Region (2026-2031)
Table 25. North America MET Inhibitors for Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America MET Inhibitors for Lung Cancer Sales by Country (2020-2025) & (K Units)
Table 27. North America MET Inhibitors for Lung Cancer Sales by Country (2026-2031) & (K Units)
Table 28. North America MET Inhibitors for Lung Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America MET Inhibitors for Lung Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe MET Inhibitors for Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe MET Inhibitors for Lung Cancer Sales by Country (2020-2025) & (K Units)
Table 32. Europe MET Inhibitors for Lung Cancer Sales by Country (2026-2031) & (K Units)
Table 33. Europe MET Inhibitors for Lung Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe MET Inhibitors for Lung Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific MET Inhibitors for Lung Cancer Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific MET Inhibitors for Lung Cancer Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific MET Inhibitors for Lung Cancer Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific MET Inhibitors for Lung Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific MET Inhibitors for Lung Cancer Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America MET Inhibitors for Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America MET Inhibitors for Lung Cancer Sales by Country (2020-2025) & (K Units)
Table 42. Latin America MET Inhibitors for Lung Cancer Sales by Country (2026-2031) & (K Units)
Table 43. Latin America MET Inhibitors for Lung Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America MET Inhibitors for Lung Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa MET Inhibitors for Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa MET Inhibitors for Lung Cancer Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa MET Inhibitors for Lung Cancer Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa MET Inhibitors for Lung Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa MET Inhibitors for Lung Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global MET Inhibitors for Lung Cancer Sales (K Units) by Type (2020-2025)
Table 51. Global MET Inhibitors for Lung Cancer Sales (K Units) by Type (2026-2031)
Table 52. Global MET Inhibitors for Lung Cancer Sales Market Share by Type (2020-2025)
Table 53. Global MET Inhibitors for Lung Cancer Sales Market Share by Type (2026-2031)
Table 54. Global MET Inhibitors for Lung Cancer Revenue (US$ Million) by Type (2020-2025)
Table 55. Global MET Inhibitors for Lung Cancer Revenue (US$ Million) by Type (2026-2031)
Table 56. Global MET Inhibitors for Lung Cancer Revenue Market Share by Type (2020-2025)
Table 57. Global MET Inhibitors for Lung Cancer Revenue Market Share by Type (2026-2031)
Table 58. Global MET Inhibitors for Lung Cancer Price (US$/Unit) by Type (2020-2025)
Table 59. Global MET Inhibitors for Lung Cancer Price (US$/Unit) by Type (2026-2031)
Table 60. Global MET Inhibitors for Lung Cancer Sales (K Units) by Application (2020-2025)
Table 61. Global MET Inhibitors for Lung Cancer Sales (K Units) by Application (2026-2031)
Table 62. Global MET Inhibitors for Lung Cancer Sales Market Share by Application (2020-2025)
Table 63. Global MET Inhibitors for Lung Cancer Sales Market Share by Application (2026-2031)
Table 64. Global MET Inhibitors for Lung Cancer Revenue (US$ Million) by Application (2020-2025)
Table 65. Global MET Inhibitors for Lung Cancer Revenue (US$ Million) by Application (2026-2031)
Table 66. Global MET Inhibitors for Lung Cancer Revenue Market Share by Application (2020-2025)
Table 67. Global MET Inhibitors for Lung Cancer Revenue Market Share by Application (2026-2031)
Table 68. Global MET Inhibitors for Lung Cancer Price (US$/Unit) by Application (2020-2025)
Table 69. Global MET Inhibitors for Lung Cancer Price (US$/Unit) by Application (2026-2031)
Table 70. Pfizer Company Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer MET Inhibitors for Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Pfizer MET Inhibitors for Lung Cancer Product
Table 74. Pfizer Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis MET Inhibitors for Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Novartis MET Inhibitors for Lung Cancer Product
Table 79. Novartis Recent Developments/Updates
Table 80. Eli Lilly and Company Company Information
Table 81. Eli Lilly and Company Description and Business Overview
Table 82. Eli Lilly and Company MET Inhibitors for Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Eli Lilly and Company MET Inhibitors for Lung Cancer Product
Table 84. Eli Lilly and Company Recent Developments/Updates
Table 85. Merck KGaA Company Information
Table 86. Merck KGaA Description and Business Overview
Table 87. Merck KGaA MET Inhibitors for Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Merck KGaA MET Inhibitors for Lung Cancer Product
Table 89. Merck KGaA Recent Developments/Updates
Table 90. AstraZeneca Company Information
Table 91. AstraZeneca Description and Business Overview
Table 92. AstraZeneca MET Inhibitors for Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. AstraZeneca MET Inhibitors for Lung Cancer Product
Table 94. AstraZeneca Recent Developments/Updates
Table 95. Takeda Pharmaceutical Company Information
Table 96. Takeda Pharmaceutical Description and Business Overview
Table 97. Takeda Pharmaceutical MET Inhibitors for Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Takeda Pharmaceutical MET Inhibitors for Lung Cancer Product
Table 99. Takeda Pharmaceutical Recent Developments/Updates
Table 100. Daiichi Sankyo Company Information
Table 101. Daiichi Sankyo Description and Business Overview
Table 102. Daiichi Sankyo MET Inhibitors for Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Daiichi Sankyo MET Inhibitors for Lung Cancer Product
Table 104. Daiichi Sankyo Recent Developments/Updates
Table 105. Kyowa Kirin Company Information
Table 106. Kyowa Kirin Description and Business Overview
Table 107. Kyowa Kirin MET Inhibitors for Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Kyowa Kirin MET Inhibitors for Lung Cancer Product
Table 109. Kyowa Kirin Recent Developments/Updates
Table 110. HUTCHMED Company Information
Table 111. HUTCHMED Description and Business Overview
Table 112. HUTCHMED MET Inhibitors for Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. HUTCHMED MET Inhibitors for Lung Cancer Product
Table 114. HUTCHMED Recent Developments/Updates
Table 115. Beyotime Biotechnology Company Information
Table 116. Beyotime Biotechnology Description and Business Overview
Table 117. Beyotime Biotechnology MET Inhibitors for Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Beyotime Biotechnology MET Inhibitors for Lung Cancer Product
Table 119. Beyotime Biotechnology Recent Developments/Updates
Table 120. Haihe Biopharma Company Information
Table 121. Haihe Biopharma Description and Business Overview
Table 122. Haihe Biopharma MET Inhibitors for Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Haihe Biopharma MET Inhibitors for Lung Cancer Product
Table 124. Haihe Biopharma Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. MET Inhibitors for Lung Cancer Distributors List
Table 128. MET Inhibitors for Lung Cancer Customers List
Table 129. MET Inhibitors for Lung Cancer Market Trends
Table 130. MET Inhibitors for Lung Cancer Market Drivers
Table 131. MET Inhibitors for Lung Cancer Market Challenges
Table 132. MET Inhibitors for Lung Cancer Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Product Picture of MET Inhibitors for Lung Cancer
Figure 2. Global MET Inhibitors for Lung Cancer Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global MET Inhibitors for Lung Cancer Market Share by Type: 2024 & 2031
Figure 4. Savolitinib Product Picture
Figure 5. Tepotinib Product Picture
Figure 6. Other Product Picture
Figure 7. Global MET Inhibitors for Lung Cancer Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global MET Inhibitors for Lung Cancer Market Share by Application: 2024 & 2031
Figure 9. Hospital
Figure 10. Drug Center
Figure 11. Others
Figure 12. Global MET Inhibitors for Lung Cancer Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global MET Inhibitors for Lung Cancer Market Size (2020-2031) & (US$ Million)
Figure 14. Global MET Inhibitors for Lung Cancer Sales (2020-2031) & (K Units)
Figure 15. Global MET Inhibitors for Lung Cancer Average Price (US$/Unit) & (2020-2031)
Figure 16. MET Inhibitors for Lung Cancer Report Years Considered
Figure 17. MET Inhibitors for Lung Cancer Sales Share by Manufacturers in 2024
Figure 18. Global MET Inhibitors for Lung Cancer Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest MET Inhibitors for Lung Cancer Players: Market Share by Revenue in MET Inhibitors for Lung Cancer in 2024
Figure 20. MET Inhibitors for Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global MET Inhibitors for Lung Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America MET Inhibitors for Lung Cancer Sales Market Share by Country (2020-2031)
Figure 23. North America MET Inhibitors for Lung Cancer Revenue Market Share by Country (2020-2031)
Figure 24. United States MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe MET Inhibitors for Lung Cancer Sales Market Share by Country (2020-2031)
Figure 27. Europe MET Inhibitors for Lung Cancer Revenue Market Share by Country (2020-2031)
Figure 28. Germany MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific MET Inhibitors for Lung Cancer Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific MET Inhibitors for Lung Cancer Revenue Market Share by Region (2020-2031)
Figure 35. China MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Southeast Asia MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Latin America MET Inhibitors for Lung Cancer Sales Market Share by Country (2020-2031)
Figure 43. Latin America MET Inhibitors for Lung Cancer Revenue Market Share by Country (2020-2031)
Figure 44. Mexico MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Brazil MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Argentina MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Middle East and Africa MET Inhibitors for Lung Cancer Sales Market Share by Country (2020-2031)
Figure 48. Middle East and Africa MET Inhibitors for Lung Cancer Revenue Market Share by Country (2020-2031)
Figure 49. Turkey MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. UAE MET Inhibitors for Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Global Sales Market Share of MET Inhibitors for Lung Cancer by Type (2020-2031)
Figure 53. Global Revenue Market Share of MET Inhibitors for Lung Cancer by Type (2020-2031)
Figure 54. Global MET Inhibitors for Lung Cancer Price (US$/Unit) by Type (2020-2031)
Figure 55. Global Sales Market Share of MET Inhibitors for Lung Cancer by Application (2020-2031)
Figure 56. Global Revenue Market Share of MET Inhibitors for Lung Cancer by Application (2020-2031)
Figure 57. Global MET Inhibitors for Lung Cancer Price (US$/Unit) by Application (2020-2031)
Figure 58. MET Inhibitors for Lung Cancer Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
